| Symbol | AKTX |
|---|---|
| Name | AKARI THERAPEUTICS PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 75/76 WIMPOLE STREET, LONDON, W1G 9RT, United Kingdom |
| Telephone | +44 2080040270 |
| Fax | — |
| — | |
| Website | https://www.akaritx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom. Additional info from NASDAQ: |
Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors
Read moreAkari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing
Read moreNew Form EFFECT - Akari Therapeutics Plc <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 9999999995-26-001192 <b>Size:</b> 1 KB
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreNew Form POS AM - Akari Therapeutics Plc <b>Filed:</b> 2026-04-10 <b>AccNo:</b> 0001493152-26-016154 <b>Size:</b> 446 KB
Read moreAkari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC
Read moreAkari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
Read moreNew Form F-6/A - Akari Therapeutics Plc <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0000919574-26-001972 <b>Size:</b> 230 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05061771 | Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct O… | Phase3 | Bullous Pemphigoid | Withdrawn | 2022-05-06 | 2022-08-01 | ClinicalTrials.gov |
| NCT04784455 | Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy | Phase3 | Thrombotic Microangiopathies | Terminated | 2021-02-01 | 2024-05-15 | ClinicalTrials.gov |
| NCT04037891 | Topical rVA576 for Treatment of Atopic Keratoconjunctivitis | Phase1 | Keratoconjunctivitis, Atopic | Terminated | 2019-03-04 | 2020-04-30 | ClinicalTrials.gov |
| NCT04035733 | rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects | Phase2 | Bullous Pemphigoid (BP) | Completed | 2018-09-25 | 2020-04-29 | ClinicalTrials.gov |
| NCT03427060 | Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 … | Phase2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | 2018-05-14 | 2021-02-03 | ClinicalTrials.gov |
| NCT03829449 | rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Terminated | 2017-03-13 | 2020-08-29 | ClinicalTrials.gov |
| NCT02591862 | Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) | Phase2 | Paroxysmal Nocturnal Haemoglobinuria (PNH) | Completed | 2016-02-01 | 2018-03-20 | ClinicalTrials.gov |